Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study.

Abstract

BACKGROUND:

Treatment of low-dose aspirin (LDA)-induced small-bowel injury has not been established. Polaprezinc, a chelate of zinc and L-carnosine, may be efficacious for such injury. We conducted a pilot randomized controlled study to investigate whether polaprezinc is effective against LDA-induced small-bowel injuries.

METHODS:

Consecutive patients under long-term (>3 months) LDA treatment and who agreed to participate in our study underwent initial capsule endoscopy (CE). Patients with LDA-induced small-bowel injury apparent upon initial CE (n = 20) were randomized into a polaprezinc (150 mg/day for 4 weeks) group and a control (no polaprezinc treatment) group. All underwent follow-up CE after 4 weeks. Changes in the number and characteristics of small-bowel mucosal injuries were compared within and between the two groups.

RESULTS:

The median number of reddened lesions and erosions/ulcers upon follow-up CE in the polaprezinc group significantly decreased (P < 0.05). However, there was no significant difference in the median number of reddened lesions and erosions/ulcers upon follow-up CE in the control group.

CONCLUSIONS:

Co-administration of polaprezinc may be effective against small-bowel mucosal injury associated with long-term LDA therapy.

• Authors: Ikue Watari, Shiro Oka, Shinji Tanaka, Taiki Aoyama, Hiroki Imagawa, Takayoshi Shishido, Shigeto Yoshida, Kazuaki Chayama
• Journal: BMC gastroenterology (BMC Gastroenterol) Vol. 13 Pg. 108 (Jul 04 2013) ISSN: 1471-230X [Electronic] England
• PMID: 23826914 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Anti-Ulcer Agents
• Organometallic Compounds
• Zinc Compounds
• polaprezinc
• Carnosine
• Aspirin

Topics

• Aged
• Aged, 80 and over
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects)
• Anti-Ulcer Agents (therapeutic use)
• Aspirin (administration & dosage, adverse effects)
• Capsule Endoscopy
• Carnosine (analogs & derivatives, therapeutic use)
• Female
• Humans
• Intestinal Mucosa (pathology)
• Intestine, Small (pathology)
• Male
• Middle Aged
• Organometallic Compounds (therapeutic use)
• Peptic Ulcer (chemically induced, drug therapy, pathology)
• Pilot Projects
• Zinc Compounds (therapeutic use)